Anaemia—low haemoglobin or red-cell count—has multiple causes: iron deficiency, vitamin B12/folate insufficiency, chronic kidney disease, autoimmune destruction, or bone-marrow failure. Treatment targets the underlying cause. Stem-cell therapies are being studied for bone-marrow-derived anaemias and autoimmune forms.
Iron-deficiency anaemia is treated with iron supplementation (ferrous sulphate, ferrous fumarate) or intravenous iron for malabsorption or GI intolerance. Vitamin B12 anaemia requires parenteral injections (IM) or high-dose oral supplements; folate deficiency responds to folic acid tablets. Chronic kidney disease anaemia responds to erythropoiesis-stimulating agents (epoetin alfa, darbepoetin alfa), though target haemoglobin levels are carefully titrated. Autoimmune haemolytic anaemia may require corticosteroids or immunosuppressants (rituximab, azathioprine). Bone-marrow failure (aplastic anaemia) is treated with immunosuppressive therapy (ATG + cyclosporine) or, if suitable, allogeneic stem-cell transplantation.
Dietary iron-rich foods (red meat, legumes, leafy greens) combined with vitamin C to enhance absorption support iron-deficiency management. Herbal tonics (nettle, yellow dock) and Chinese herbal formulations are used anecdotally for blood-building. Acupuncture is promoted for qi-deficiency anaemia in traditional systems, though evidence is weak.
Haematopoietic stem-cell transplantation is established for aplastic anaemia and marrow-failure syndromes. Autologous and allogeneic approaches are being studied for refractory autoimmune anaemias. Mesenchymal stem cells may modulate immune destruction in some cases. These remain investigational for non-transplant anaemias. Review candidacy criteria with your haematologist.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Oral iron supplementation (ferrous salts) | Standard | Strong | €30–80/year | Low | None |
| Intravenous iron (iron sucrose, iron carboxymaltose) | Standard | Strong | €400–800 per course | Low | None |
| Vitamin B12 injections (IM) | Standard | Strong | €200–400/year | Low | None |
| Erythropoiesis-stimulating agent (EPO, darbepoetin) | Standard | Strong | €2,000–5,000/year | Low | None |
| Dietary iron optimisation + vitamin C | Alternative | Moderate | €0–100/year | Low | None |
| Haematopoietic stem-cell transplantation | Standard | Strong | €80,000–150,000 | High | 6–12 weeks |
| Mesenchymal stem-cell immunomodulation (autoimmune) | Regenerative | Investigational | €12,000–28,000 (trial-dependent) | Medium | 2–4 weeks |
Haematopoietic stem-cell transplantation is the formal term; bone-marrow transplant is a source. Peripheral blood stem cells are now more commonly used due to faster recovery.
Some early trials show immune tolerance induction with mesenchymal stem cells, but curative results are not yet established. Corticosteroids and immunosuppressants remain first-line.
Oral iron typically shows improvement within 2–4 weeks; full haemoglobin recovery takes 2–3 months. Intravenous iron works faster, with effects within 1–2 weeks.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية